Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2008

01-07-2008 | Case Reports

A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib

Authors: Ramón González Manzano, Elena Martínez Navarro, Elena Eugenieva, Francisco José Fernández Morejón, José Farré, Antonio Brugarolas

Published in: Clinical and Translational Oncology | Issue 7/2008

Login to get access
Metadata
Title
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib
Authors
Ramón González Manzano
Elena Martínez Navarro
Elena Eugenieva
Francisco José Fernández Morejón
José Farré
Antonio Brugarolas
Publication date
01-07-2008
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 7/2008
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-008-0229-2

Other articles of this Issue 7/2008

Clinical and Translational Oncology 7/2008 Go to the issue

Reviews

Clinical application of intensity-modulated radiotherapy for head and neck cancer

Research Articles

High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer

Educational Series

Circulating tumor cells in breast cancer: methodology and clinical repercussions

Case Reports

Clinical case report and literature review: metachronous colorectal splenic metastases

Editorial

Research in oncology: legal and ethical aspects

Educational Series

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits